Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IPG7236 combined with toripalimab in adults with advanced solid tumors
CTR20261250Phase 2Active
- Sponsor
- Aimed Bio
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IPG7236, toripalimab in Nonhematologic neoplasms, sponsored by Aimed Bio. Started Jun 2026; status: active.
02
Drugs
IPG7236toripalimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20261250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261250.